Venture Capital News Daily
   Your Source for Venture Capital and Private Equity Financings
   Massinvestor/VC News Daily      
   Venture Capital News Daily on RSS Venture Capital News Daily on Facebook Venture Capital News Daily on Twitter
VC DATABASE   /   MOBILE APP  /  CELEBRITY VCs   /   VENTURE TRACKR   /   ARCHIVE   /   ABOUT US
Venture Capital News Daily
Generation Bio Raises $100M

       
CAMBRIDGE, MA, Generation Bio, a developer of genetic medicines, has secured $100 million in Series B financing.
Click here for more funding data on Generation Bio
To export Generation Bio funding data to PDF and Excel, click here
Generation Bio, a company developing the first genetic medicines that can be titrated to effect and re-dosed for a lifetime of benefit, today announced the closing of a $100 million Series B financing. Proceeds will be used to move Generation Bio's first two therapeutic candidates through Investigational New Drug (IND) enabling studies and to advance additional programs targeting genetic diseases of the retina, central nervous system and lungs.

"We are delighted to have the support of this group of expert, long-term investors who share our vision to create a generation of people living unaffected by genetic disease," said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. "This will be a critically important year for us as we develop the GeneWave platform and work towards our first development candidates to address rare diseases of the liver. The round will also support the development of approaches to deliver ceDNA to other tissues such as the eye, the central nervous system and the lungs."

Generation Bio is developing its proprietary GeneWave technology to create a new class of genetic medicines that can be titrated to effect and re-dosed to optimally impact each patient's disease from birth to adulthood with durable transgene expression. These therapies are designed to overcome the immunogenicity associated with viral-vector gene therapies, which has historically limited the number of patients that can be treated and prevented re-dosing. Since its founding in 2016, Generation Bio has demonstrated durable, dose-dependent expression and the ability to increase expression in the liver with re-dosing in vivo with the GeneWave platform.

"Generation Bio is creating a breakthrough category of therapeutics and is positioned to be a leader in the gene therapy field," said Jason Rhodes, a partner at Atlas Venture and a founder and chairman of Generation Bio's board of directors. "We are excited to have this exceptional group of investors join our efforts to create the first-ever genetic medicines with drug-like properties."

About Generation Bio
Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people unaffected by inherited disease. The company's therapies are based on its proprietary GeneWave technology, which delivers durable, high levels of gene expression and can be re-dosed to titrate to effect and to sustain impact over a lifetime. Generation Bio was founded and launched by Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.generationbio.com or follow @lifetimegenetx.
(c)2011-2018 by Massinvestor, Inc. For contact info, please check out our about page.
  >> Click here for in-depth research on 4,000 VC firms
Venture Capital News Daily
 
Massinvestor/VC News Daily
617-620-4606


© 2018 Massinvestor, Inc.